Details of the Drug

General Information of Drug (ID: DMK0UOY)

Drug Name

ME-401

Synonyms

Zandelisib; UNII-8Z28M5SX0X; 8Z28M5SX0X; 4-yl)-1,3,5-triazin-2-amine; 1401436-95-0; [2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl}-6-(morpholin-; 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-{2-methyl-1-; Zandelisib [INN]; Zandelisib [USAN]; SCHEMBL12936730; GTPL10627; ACC-524; PWT-143; ME401; PW-143; WHO 11202; ZINC148868634; Example 51 [WO2012135160A1]; HY-109198; CS-0119144; A35 [WO2012135160A1]; 1,3,5-Triazin-2-amine, 4-(2-(difluoromethyl)-1H-benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)-; 4-(2-(Difluoromethyl)benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1,3,5-triazin-2-amine; 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine

Indication

Disease Entry	ICD 11	Status	REF
Follicular lymphoma	2A80	Phase 2	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 1	[2]
Diffuse large B-cell lymphoma	2A81	Phase 1	[2]
Lymphoma	2A80-2A86	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C31H38F2N8O
Canonical SMILES: CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F
InChI: 1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)
InChIKey: WPFUFWIHMYZXSF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 66571003
CAS Number: 1401436-95-0
TTD ID: D8IQ0D

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase delta (PIK3CD)	TTGBPJE	PK3CD_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Follicular lymphoma

ICD Disease Classification

2A80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
PI3-kinase delta (PIK3CD)	DTT	PIK3CD	4.31E-16	-0.37	-0.91

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03768505) Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)